Despite a steady stream of hype and "pockets" of change, most cardiologists aren’t seeing the transformation that Silicon Valley promised. ACC CIO John Rumsfeld, MD, PhD, explains what's missing and why engaging clinical partners could help.
Artificial intelligence may be perceived as a threat to some physicians, but, according to research presented at the Radiological Society of North America’s annual meeting in Chicago, it could have some real use for cardiologists.
People with severe but stable ischemic heart disease don’t benefit any more from invasive CV procedures than they do from optimal medical therapy and lifestyle changes alone, according to results from the highly anticipated ISCHEMIA trial.
Medicine is moving farther from its fee-for-service roots and closer to more individualized, value-based care—a phenomenon that could benefit a growing number of home-based care programs, according to data presented at MedAxiom’s CV Transforum.
Remote monitoring and high-tech health management solutions have dominated cardiology headlines for the better part of the past year, touted for their accessibility and preventive benefits. But that vision of remote monitoring as the future of CV care might be a skewed representation of our current reality.
The past year has seen a whole lot of change for the field of cardiology, but it’s hard to discern where that leaves us as we prepare for 2020. MedAxiom President Jerry Blackwell, MD, MBA, helped clarify the situation.
The notion of a digital transformation in cardiology, and healthcare as a whole, is an appealing one. But data presented at MedAxiom’s CV Transforum last week suggests we’re further away from a transformation than we might think.
Urine flow rate-guided hydration, as opposed to left ventricular end-diastolic pressure-guided hydration, could prevent more complications in CKD patients who are at a high risk for contrast-induced kidney injury.
Results from the late-breaking TWILIGHT trial suggest that, among high-risk patients who have undergone PCI and completed three months of dual antiplatelet therapy, it’s safer to continue treatment with ticagrelor alone rather than add aspirin to that cocktail.
Patients with severe aortic stenosis who undergo TAVR enjoy a minor but significant sustained health benefit that isn’t mirrored in patients who opt for surgical AVR, according to research reported at TCT 2019 in San Francisco.